0000911916-17-000074.txt : 20170301 0000911916-17-000074.hdr.sgml : 20170301 20170301121630 ACCESSION NUMBER: 0000911916-17-000074 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170301 FILED AS OF DATE: 20170301 DATE AS OF CHANGE: 20170301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CoLucid Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348649 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203419541 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 781-365-2596 MAIL ADDRESS: STREET 1: 222 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Colucid Pharmaceuticals Inc DATE OF NAME CHANGE: 20060104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lawton Alison Frances CENTRAL INDEX KEY: 0001542650 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37358 FILM NUMBER: 17652635 MAIL ADDRESS: STREET 1: 39 ROBINSON ROAD CITY: LEXINGTON STATE: MA ZIP: 02420 FORMER NAME: FORMER CONFORMED NAME: LAWTON ALISON FRANCIS DATE OF NAME CHANGE: 20120216 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2017-03-01 1 0001348649 CoLucid Pharmaceuticals, Inc. CLCD 0001542650 Lawton Alison Frances C/O COLUCID PHARMACEUTICALS, INC. 222 THIRD STREET CAMBRIDGE MA 02142 1 0 0 0 Stock Option (Right to Buy) 6.54 2017-03-01 4 D 0 1420 39.96 D 2026-03-11 Common Stock 1420 0 D Stock Option (Right to Buy) 6.24 2017-03-01 4 D 0 8897 40.26 D 2026-05-10 Common Stock 8897 0 D Stock Option (Right to Buy) 36.20 2017-03-01 4 D 0 658 10.30 D 2027-01-03 Common Stock 658 0 D Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. /s/ Christine G. Long, Attorney-in-Fact for Alison Lawton (power of attorney previously filed) 2017-03-01